Researchers from CSIC have developed a chimeric protein (ClyRODI-H5) with an improved lytic
activity against Staphylococcus sp. and higher stability than the parental endolysins of the state of the
art. Thus, the invention relates to this chimeric protein and its use as an antimicrobial for treating
and/or preventing staphylococcal infections without generation of resistant bacteria; for removing
and/or preventing staphylococcal biofilms formation on abiotic surfaces, or for removing and/or
preventing staphylococcal contamination of foods. Thus, the present invention belongs to the field of
the treatment of bacterial contamination and/or infections.
Industrial partners or companies from the food or pharmaceutical field are being sought to collaborate
through a patent license agreement.
An offer for Patent Licensing
ClyRODI-H5: A protein to kill Staphylococcus aureus
Control ClyRODI-H5 Staphylococcal removal after 5 min of treatment with 0.1 µM of ClyRODI-H5 The rapid rise and dissemination of multi-drug resistant (MDR) pathogens represents an urgent global risk for human health, sustainable food production and development. S. aureus is one of the major bacterial agents causing foodborne diseases in humans and many types of infections.
Moreover, its ability to form biofilms onto different surfaces makes this bacterium difficult to eradicate. The study of bacteriophage-encoded lytic proteins (endolysins), able to kill the bacteria through peptidoglycan degradation followed by osmotic lysis, has attracted great interest in the last years. Phage lytic proteins have even been proposed as disinfectants for the food industry. The rapid bactericidal action and biodegradability of phage enzyme-based antimicrobials are appealing features. In this regard, here we have constructed a new chimeric protein (ClyRODI-H5) that comprises a catalytic domain (CHAP) from the endolysin LysRODI and a cell wall binding domain (SH3) from endolysin LysH5.
Main innovations and advantages
· The chimeric lytic protein ClyRODI-H5 shows increased activitycompared to the parental endolysins: 3 and 24-fold higher thanLysRODI and LysH5 respectively. It is active against S. aureus includingmethicillin-resistant S. aureus, and also against other staphylococcalspecies.
· A low concentration (0.1 µM) of CLyRODI-H5 lyses the staphylococcalpopulations in a very short period of time, achieving a completebacterial removal (106 CFU/ml) in 5 min. Besides, the addition of sub-lethal doses of the protein does not trigger staphylococcal resistance atin vitro conditions.
· ClyRODI-H5 is stable in a broader range of pH from 3 to 11, keepingits activity unaltered.
· The addition of ClyRODI-H5 (0.7 µM) strongly prevented (98%) thebiofilm formation onto polystyrene. Moreover, the treatment of pre-formed biofilms with 2.5 µM of the protein was able to remove the
The Spanish National Research Council (in Spanish 'Consejo Superior de Investigaciones Científicas (CSIC)') is a government agency for basic and applied scientific research.
It is the largest public research organization in Spain, with presence in all the Autonomous Communities through 126 centers and 145 associated units.
Create your free account to connect with CSIC - Consejo Superior de Investigaciones Científicas and thousands of other innovative organizations and professionals worldwide
Send a request for information
to CSIC - Consejo Superior de Investigaciones Científicas
Technology Offers on Innoget are directly posted
and managed by its members as well as evaluation of requests for information. Innoget is the trusted open innovation and science network aimed at directly connect industry needs with professionals online.
Need help requesting additional information or have questions regarding this Technology Offer?
Contact Innoget support
